DermsDevelopments Overview

  • Founded
  • 2006
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 1
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $30.4M
Latest Deal Amount

DermsDevelopments General Information

Description

Supplier of dermatology products. The company provides and distributes pharmaceutical products through its two main brands ZindaclinTM and VitixTM.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Personal Products
Other Industries
Distributors/Wholesale (B2C)
Other Healthcare
Acquirer
York Pharma
Primary Office
  • King Edward Court, King Edward Road
  • Knutsford WA16 0BE
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

DermsDevelopments Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 09-Oct-2007 $30.4M 000.00 Completed
1. Buyout/LBO Completed
To view DermsDevelopments’s complete valuation and funding history, request access »

DermsDevelopments Executive Team (2)

Name Title Board Seat Contact Info
Richard Anderson Founder & Chief Executive Officer
Christopher Evans Founder
To view DermsDevelopments’s complete executive team members history, request access »

DermsDevelopments Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DermsDevelopments Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Excalibur Group Holdings Venture Capital Majority 000 0000 000000 0
To view DermsDevelopments’s complete investors history, request access »